SG11202108403UA - Anti-clec2d antibodies and methods of use thereof - Google Patents

Anti-clec2d antibodies and methods of use thereof

Info

Publication number
SG11202108403UA
SG11202108403UA SG11202108403UA SG11202108403UA SG11202108403UA SG 11202108403U A SG11202108403U A SG 11202108403UA SG 11202108403U A SG11202108403U A SG 11202108403UA SG 11202108403U A SG11202108403U A SG 11202108403UA SG 11202108403U A SG11202108403U A SG 11202108403UA
Authority
SG
Singapore
Prior art keywords
seq
antibody
antigen
clec2d
binding fragment
Prior art date
Application number
SG11202108403UA
Other languages
English (en)
Inventor
Kavitha Iyer Rodrigues
Maloy Ghosh
Sunit Maity
Yogendra Manjunath Bangalore Muniraju
Sathyabalan Murugesan
Sanghamitra Bhattacharjee
Vivek Halan
Subhra Prakash Chakrabarty
Ashvini Kumar Dubey
Anurag Tiwari
Kirthana Mysore Vasudevarao Sindhe
Pallavi Lahiri
Sahana Bhima Rao
Prachi *
Shruti Srivastava
Rao Shreesha Ramesh
Bharath Ravindra Shenoy
Nikitha Markanda
Bhagyashree Dikey
Bairavabalakumar Natarajan
Original Assignee
Zumutor Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zumutor Biologics Inc filed Critical Zumutor Biologics Inc
Publication of SG11202108403UA publication Critical patent/SG11202108403UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202108403UA 2019-02-11 2020-02-10 Anti-clec2d antibodies and methods of use thereof SG11202108403UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201941005395 2019-02-11
PCT/US2020/017518 WO2020167668A1 (en) 2019-02-11 2020-02-10 Anti-clec2d antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11202108403UA true SG11202108403UA (en) 2021-08-30

Family

ID=69811875

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108403UA SG11202108403UA (en) 2019-02-11 2020-02-10 Anti-clec2d antibodies and methods of use thereof

Country Status (9)

Country Link
US (2) US11827710B2 (cg-RX-API-DMAC7.html)
EP (1) EP3924385A1 (cg-RX-API-DMAC7.html)
JP (2) JP7612591B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220007584A (cg-RX-API-DMAC7.html)
AU (1) AU2020222891B2 (cg-RX-API-DMAC7.html)
CA (1) CA3129818A1 (cg-RX-API-DMAC7.html)
IL (1) IL285401A (cg-RX-API-DMAC7.html)
SG (1) SG11202108403UA (cg-RX-API-DMAC7.html)
WO (1) WO2020167668A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220007584A (ko) 2019-02-11 2022-01-18 주무토르 바이오로직스 인코포레이티드 항-clec2d 항체 및 이의 사용 방법
CN115443140A (zh) * 2020-04-02 2022-12-06 苏州恒康生命科学有限公司 人ror-1抗体和抗ror-1-car-t细胞
US20230374142A1 (en) * 2020-10-05 2023-11-23 Monash University CLEC9A antibodies
CN116997561A (zh) * 2021-03-24 2023-11-03 森永乳业株式会社 肽及含有该肽作为有效成分的组合物
US20240398902A1 (en) * 2021-09-13 2024-12-05 Achelois Biopharma, Inc. Multivalent interferon particles compositions and methods of use
CN114685663B (zh) * 2022-04-07 2023-09-08 西南大学 一种抗胆固醇依赖性细胞溶素的抗体及其应用
WO2023233330A1 (en) * 2022-05-31 2023-12-07 Pfizer Inc. Anti-bmp9 antibodies and methods of use thereof
KR20250122456A (ko) * 2022-11-01 2025-08-13 프로비던스 헬스 앤드 서비시즈 - 오레곤 Fas 리간드에 특이적인 단일클론 항체 및 이의 용도
CN115894675B (zh) * 2023-02-03 2023-11-14 康复大学(筹) 新冠病毒SARS-CoV-2核衣壳蛋白单克隆抗体及其应用
AU2024263454A1 (en) * 2023-04-24 2025-12-11 Elpis Biopharmaceuticals Armored anti-b7h3 car-t cells and uses thereof in cancer therapy
WO2025096542A2 (en) * 2023-10-30 2025-05-08 Immunitas Therapeutics, Inc. Clec2d binding proteins and related methods
WO2026050637A1 (en) * 2024-08-29 2026-03-05 Elpis Biopharmaceuticals Chimeric antigen receptor targeting interleukin- 13 receptor subunit alpha-2 and optionally b7h3 for treating glioblastoma
WO2026064353A1 (en) * 2024-09-17 2026-03-26 The Board Of Regents Of The University Of Texas System Diagnostics and therapeutics targeting slc13a3

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
JPH10501681A (ja) 1994-02-22 1998-02-17 ダナ−ファーバー キャンサー インスティチュート 核酸送達システムならびにその合成および使用方法
US7147854B2 (en) 1997-06-23 2006-12-12 Yes Biotech Laboratories Ltd. Topical treatment of psoriasis using neutralizing antibodies to interleukin-8
US20040001804A1 (en) * 1999-12-30 2004-01-01 Mathew Porunelloor A. LLT uses thereof in immune system modulation
WO2012000994A1 (en) * 2010-06-29 2012-01-05 C.N.R.S. Llt-1 antibodies with new functional properties
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device
KR20220007584A (ko) * 2019-02-11 2022-01-18 주무토르 바이오로직스 인코포레이티드 항-clec2d 항체 및 이의 사용 방법

Also Published As

Publication number Publication date
US20200291120A1 (en) 2020-09-17
JP7875933B2 (ja) 2026-06-18
AU2020222891A1 (en) 2021-08-05
US11827710B2 (en) 2023-11-28
JP2022521705A (ja) 2022-04-12
KR20220007584A (ko) 2022-01-18
CA3129818A1 (en) 2020-08-20
JP7612591B2 (ja) 2025-01-14
US12460007B2 (en) 2025-11-04
AU2020222891B2 (en) 2026-07-16
EP3924385A1 (en) 2021-12-22
NZ778293A (en) 2026-02-27
US20240010733A1 (en) 2024-01-11
WO2020167668A1 (en) 2020-08-20
IL285401A (en) 2021-09-30
JP2025062598A (ja) 2025-04-14

Similar Documents

Publication Publication Date Title
US12460007B2 (en) Antibodies that bind to C-type lectin domain family 2 member D (CLEC2D)
JP7440569B2 (ja) 癌の治療に用いるための細胞傷害誘導治療剤
CN113227146B (zh) 密蛋白18.2结合部分和其用途
JPWO2020138489A1 (ja) 新規抗ccr8抗体
JP2024091842A (ja) 抗cd3抗体及び該抗体を含む分子
IL322492A (en) New anti-PD-1 antibodies
TWI894643B (zh) 抗cd147抗體、醫藥組成物、該等之用途及抗cd147抗體之製造方法
WO2017086367A1 (ja) 免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法
JP7036729B2 (ja) 治療用抗cd9抗体
RS57279B1 (sr) Anti-b7-h3 antitelo
CN114126626A (zh) 多特异性结合蛋白
JP2019512207A (ja) Foxp3由来のペプチドに特異的なt細胞受容体様抗体
CA2960466A1 (en) Cancer cell-specific antibody, anticancer drug and cancer testing method
WO2018094143A1 (en) Glycan-interacting compounds and methods of use
KR20210108972A (ko) 항페리오스틴 항체 및 이의 용도
US20240059797A1 (en) Engineered multi-specific antibodies and related methods of use and manufacture
KR102480815B1 (ko) 바이안테나리 루이스 b 및 루이스 y 항원에 결합하는 치료 항체
HK40102796A (en) Cell injury inducing therapeutic drug for use in cancer therapy
Nilvebrant et al. IBC’s 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of the Antibody Society, December 5–8, 2011, San Diego, CA
HK1258783B (en) Cell injury inducing therapeutic drug for use in cancer therapy
WO2026022767A1 (ko) B7-h3을 표적하는 항체, 및 이를 포함하는 키메라 항원 수용체
JP2023509973A (ja) 上皮カドヘリン特異性抗体
HK1228935B (en) Immunoactivating antigen-binding molecule